Arcutis Biotherapeutics, Inc. ARQT Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s cash & equivalents?
- Arcutis Biotherapeutics, Inc. (ARQT) reported cash & equivalents of $35.07M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s cash & equivalents changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s cash & equivalents decreased by 34.7% year-over-year, from $53.72M to $35.07M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s cash & equivalents has grown at a -8.3% compound annual growth rate (CAGR), from $66.62M to $43.22M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.